



IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED *1646*
#21653
ply
5.02

DEC 04 2001

TECH CENTER 1600/2900

APPLICANT(S): Burton G. Christensen et al.

SERIAL NO.: 09/776,466

FILING DATE: February 2, 2001

TITLE: Glycopeptide Derivatives

EXAMINER: Unknown

GROUP ART UNIT: 1646

ATTY. DOCKET NO.: AMI-087-R

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231, on the date shown below:

Dated: October 25, 2001

By: Linda Fall
Linda Fall

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is a modified form PTO-1449 listing documents for consideration by the Examiner. A copy of each of the listed documents is also enclosed herewith.

Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of the non-English language document, Fukuzawa et al., Tennen Yuki Kagobutsi Toronkai Koen Yoshishu 40th 151-156 (1998), is provided as follows:

Among other information, Fukuzawa et al. discloses the synthesis, activity and mechanism of action of glucose-C-6 modified vancomycin derivatives.

A translation of Fukuzawa et al. is also enclosed pursuant to 37 CFR §1.98(a)(3)(ii).

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Consideration of the listed documents and an early action on the merits is respectfully requested. Additionally, the Examiner is requested to return an initialled copy of the enclosed form PTO-1449 to Applicants.

Respectfully submitted,

Dated: 10/25/01

Advanced Medicine, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080
650/808-6000 Telephone
650/808-6078 Fax

By: Jeffrey A. Hagenah
Jeffrey A. Hagenah
Reg. No. 35,175